Excerpt from OncLive:
“Lurbinectedin (Zepsyre; PM1183) plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer (SCLC), especially when excluding refractory patients.
“In particular, patients with chemotherapy-free intervals (CTFIs) of 90 days or more induced a 53% overall response rate (ORR) and PFS of 5.7 months, according to findings that were presented at the 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.”
Go to full article published by OncLive on Sep 26, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.